Abecma (idecabtagene vicleucel) — Medical-benefit prior authorization and coverage criteria
Customize your policy alerts
Sign up for all UCare policy alerts
Know when UCare releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical-benefit prior authorization and coverage criteria for Abecma (idecabtagene vicleucel) for UCare Medical Assistance and Exchange Plans, applicable to adults with relapsed or refractory multiple myeloma after prior therapies.
No material clinical or coverage changes in this revision.
Recommended Authorization Criteria
Initial therapy (FDA-approved indication)
Covered when ALL of the following are met for a single dose:
Approve a single dose up to 510 x 10^6 CAR-positive T-cells administered IV.
Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria.
| Regimen | Dose / Administration | Line of therapy / Prior regimens | Coverage |
|---|---|---|---|
| Abecma (idecabtagene vicleucel) as a single IV infusion | Approve a single dose up to 510 x 10^6 CAR‑positive T‑cells administered intravenously | Previously treated multiple myeloma: either (1) ≥2 prior lines of systemic therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti‑CD38 monoclonal antibody; OR (2) ≥3 prior lines of therapy | Covered with criteria — prior authorization required; medication must be prescribed by or in consultation with an oncologist; lymphodepleting chemotherapy received or planned prior to infusion; patient ≥18 years; no prior CAR‑T therapy |
Dose and Coding Details
Provider Requirements and Authorization
Prior authorization required for medical benefit coverage
Prior authorization is recommended for medical benefit coverage; approval requires that the patient meet the listed authorization criteria and dosing for the FDA-approved multiple myeloma indication. Approval also requires that the medication be prescribed by or in consultation with an oncologist and is issued for a 6-month duration to allow preparation and administration of a single dose.
- Approval is contingent on meeting all elements of the FDA-approved indication (age ≥18, required prior lines of therapy, lymphodepleting chemotherapy, no prior CAR‑T, and oncologist prescription).
- Approval duration: 6 months to allow preparation and administration of one dose.
Step therapy note — no additional step requirements
Step therapy does not impose additional sequential drug trial requirements beyond the clinical eligibility that specifies required prior lines of systemic therapy (either ≥2 lines including an immunomodulatory agent, a proteasome inhibitor, and an anti‑CD38 antibody, or ≥3 prior lines).
- Clinical eligibility already requires prior lines of systemic therapy as part of the authorization criteria.
Specialist prescription / consultation required for approval
Prior authorization approval requires the medication be prescribed by or in consultation with a physician who specializes in the condition being treated (oncologist) due to the specialized evaluation, monitoring, and administration needs for CAR‑T therapy.
- Specialist involvement (prescribing or consultation by an oncologist) is required for approval.
- Rationale cited: specialized skills for evaluation, diagnosis, monitoring adverse events, and preparing/administering therapy.
Denial risk if authorization criteria are not met
Coverage is not recommended for situations that are not listed in the Recommended Authorization Criteria; failure to meet any required authorization criteria may result in denial of coverage.
- If the patient does not meet all elements of the FDA‑approved indication (A–E), coverage is not recommended.
- Criteria will be updated as new published data are available.
Clinical Background
Abecma (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T‑cell immunotherapy (CAR‑T) indicated for adult patients with relapsed or refractory multiple myeloma after prior therapies. It carries boxed warnings for cytokine release syndrome, neurologic toxicity, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, prolonged cytopenias, and a risk of T‑cell malignancies.
Key Terms
Eligible Line(s) of Therapy
second-line or later
Policy Revision History
Policy last reviewed on 03/11/2026 (annual revision) with no clinical criteria changes noted.
Annual revision on 03/05/2025: Added an option allowing approval for patients who have received at least three prior lines of therapy.
Selected revision on 05/29/2024: Revised indication criteria from requiring four or more prior systemic therapy lines to two or more lines; dose revised from up to 460 x10^6 to up to 510 x10^6 CAR-positive T-cells.
UCare P&T committee review on 09/16/2024: Policy reviewed and approved (annual review process).
Annual revision on 03/29/2023 with no clinical criteria changes noted.
Policy effective date established as 07/01/2021.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.